ABSTRACT

Background: With increasing utilization of cannabis in the United States (US), clinicians may encounter more cases of Gastroparesis (GP) in coming years.

Objective: The primary outcome was inpatient mortality for GP with cannabis use. Secondary outcomes included system-based complications and the burden of the disease on the US healthcare system.

Methods: From the Nationwide Inpatient Sample (NIS), we identified adult hospitalizations with a primary discharge diagnosis of GP for 2016 and 2017. Individuals ≤18 years of age were excluded. The study population was subdivided based on a secondary diagnosis of cannabis use. The outcomes included biodemographic characteristics, mortality, complications, and burden of disease on the US healthcare system.

Results: For 2016 and 2017, we identified 99,695 hospitalizations with GP. Of these hospitalizations, 8,870 had a secondary diagnosis of cannabis use while 90,825 served as controls. The prevalence of GP with cannabis use was 8.9%. For GP with cannabis use, the patients were younger (38.5 vs 48.1 years, p < 0.001) with a Black predominance (Table 1) and lower proportion of females (52.3 vs 68.3%, p < 0.001) compared to the non-cannabis use cohort. Additionally, the cannabis use cohort had higher percentage of patients with co-morbidities like hypertension, diabetes mellitus and a history of smoking. The inpatient mortality for GP with cannabis use was noted to be 0.27%. Furthermore, we noted shorter mean length of stay (LOS) (3.4 vs 4.4 days, aMD: −0.7, 95%CI: −0.9 – [−0.5], p < 0.001), lower mean total hospital charge (THC) ($30,400 vs $38,100, aMD: −5100, 95%CI: −6900 – [−3200], p < 0.001), and lower rates of sepsis (0.11 vs 0.60%, aOR: 0.22, 95% CI: 0.05–0.91, p = 0.036) for GP hospitalizations with cannabis use compared to the non-cannabis use cohort.

Conclusion: Inpatient mortality for GP hospitalizations with cannabis use was 0.27%. Additionally, these patients had shorter LOS, lower THC, and lower sepsis rates.

摘要

背景：随着美国（US）大麻使用量的增加，未来几年临床医生可能会遇到更多的胃轻瘫（GP）病例。

目的：主要结果是使用大麻的 GP 住院死亡率。次要结果包括基于系统的并发症和疾病对美国医疗保健系统的负担。

方法：从全国住院患者样本 (NIS) 中，我们确定了 2016 年和 2017 年首次出院诊断为 GP 的成人住院患者。排除了 18 岁以下的个体。根据对大麻使用的二次诊断，对研究人群进行了细分。结果包括美国医疗保健系统的生物人口学特征、死亡率、并发症和疾病负担。

结果：在 2016 年和 2017 年，我们确定了 99,695 例全科医生住院治疗。在这些住院治疗中，8,870 人二次诊断为使用大麻，而 90,825 人作为对照。使用大麻的 GP 患病率为 8.9%。对于使用大麻的 GP，与不使用大麻的患者相比，患者更年轻（38.5 岁与 48.1 岁，p < 0.001），黑人占优势（表 1），女性比例较低（52.3 与 68.3%，p < 0.001）队列。此外，使用大麻的人群中患有高血压、糖尿病和吸烟史等并发症的患者比例更高。使用大麻的 GP 住院死亡率为 0.27%。此外，我们注意到平均住院时间 (LOS) 较短（3.4 天对 4.4 天，aMD：-0.7，95%CI：-0.9 – [-0.5]，p < 0.001），平均住院总费用 (THC) 较低（$30,400与 38,100 美元相比，

结论：因使用大麻而住院的 GP 住院死亡率为 0.27%。此外，这些患者的 LOS 更短，THC 更低，败血症率更低。